Xin Lang Cai Jing·2025-11-27 06:13Core Insights - Junshi Biosciences experienced a slight increase in stock price by 0.46% on November 26, with a trading volume of 294 million yuan [1] - The company reported a net financing purchase of 6.65 million yuan on the same day, indicating strong investor interest [1] Financing Overview - On November 26, Junshi Biosciences had a financing buy-in amount of 25.51 million yuan, with a total financing balance of 13.80 billion yuan, representing 4.86% of its market capitalization [1] - The financing balance is above the 80th percentile of the past year, indicating a high level of leverage [1] Short Selling Activity - On the same day, Junshi Biosciences saw a short selling repayment of 7,320 shares and a short selling amount of 1,623 shares, totaling 60,200 yuan in sales [1] - The remaining short selling volume was 30,390 shares, with a short selling balance of 11.27 million yuan, also above the 80th percentile of the past year [1] Company Profile - Junshi Biosciences, established on December 27, 2012, focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [2] - The company's revenue composition includes 90.67% from drug sales, 8.74% from technology licensing, and 0.59% from technical services [2] Financial Performance - For the period from January to September 2025, Junshi Biosciences reported a revenue of 1.806 billion yuan, a year-on-year increase of 42.06% [2] - The company recorded a net loss attributable to shareholders of 596 million yuan, which is a 35.72% increase compared to the previous year [2] Shareholder Information - As of September 30, 2025, Junshi Biosciences had 35,900 shareholders, an increase of 15.17% from the previous period [2] - The average number of circulating shares per shareholder decreased by 12.96% to 21,361 shares [2]